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Introduction: Systemic lupus erythematosus (SLE) is an autoim-
mune disease characterized by an acquired IL-2 deﬁciency in the
peripheral lymphoid organs and peripheral blood of murine and
human SLE (Humrich et al. 2010, von Spee-Mayer et al. 2015).
Kidney-inﬁltrating CD4+T cells play a crucial role in the progres-
sion of lupus nephritis (LN). However, the role of kidney- inﬁl-
trating T cells in the pathogenesis of LN is still not completely
understood. The aim of this study was to investigate whether an IL-
2 deﬁciency is also present in the inﬂamed kidney, thereby
contributing to an impaired intrarenal Treg function and renal
inﬂammation. Furthermore it was investigated if an IL-2-based
immunotherapy can directly act on intrarenal Treg and whether
this has consequences on the kidney inﬂammation.
Methods: Intrarenal CD4+ T cells phenotype of (NZBxNZW) F1
mice (NZB/W) with active LN was assessed and the in vitro IL-2
production of intrarenal CD4+CD44+ T cells were determined by
ﬂow cytometry. Furthermore, NZB/W mice were treated with re-
combinant IL-2 for a total of 31 days. Kidneys were histological
scored using the activity index (AI) and the intrarenal CD4+ T cell
phenotype was assessed in IL-2 treated mice compared to control
mice.
Results: Intrarenal Treg exhibit characteristic signs of IL-2 depri-
vation in parallel to a progressive hyperactivity of intrarenal Tcon
with disease progression. These Treg defects were associated with a
diminished production of IL-2 and an increased production of IFNg
by kidney-inﬁltrating Tcon. Furthermore, IL-2 therapy could in-
crease the frequency of intrarenal natural CD25+Helios+Treg,
strongly reduced the hyperactivity of intrarenal Tcon, ultimately
resulted in a reduced histological AI and prolonged the survival of
IL-2 treated lupus mice.
Conclusions: Our data indicate that on the one hand an IL-2 deﬁ-
ciency is also present in the inﬂamed kidney, thereby contributing
to renal inﬂammation. On the other hand, long term IL-2 treatment
is able to reduce hyperactivity of intrarenal Tcon and to diminish
kidney inﬂammation in lupus prone mice. This shows the close
relation between intrarenal IL-2 deﬁciency and resultant Treg de-
fects, the Tcon hyperactivity and the severity of LN. These results
also provide additional rationales for an IL-2 based immunotherapy
to treat patients with SLE, in particular with renal involvement.
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temic lupus erythematosus (SLE) that is usually treated with an
extended course of intravenous (IV) cyclophosphamide (CYC).
Given the side effects of high dose cyclophosphamide, we evaluated
the efﬁcacy of a course of low ﬁxed dose IV CYC prescribed as a
remission-inducing treatment, followed by (AZA) as a remission-
maintaining agent.
Methods: In this single center retrospective (january 2010 to
january 2014) clinical study, we evaluated 40 SLE patients with
proliferative glomerulonephritis who were given ﬁxed low dose IV
CYC regimen (500 mg 6 monthly pulses) followed by azathioprine
(AZA). AZA (2mg/kg/day) was started 2 weeks after the last CYC
injection. Oral prednisone was also given, beginning at a dose of
1 mg/kg per day and then tapering over a period of months to
alternate-day low dose maintenance therapy. Remission was deﬁned
as <10 red blood cells per high power ﬁeld, no cellular casts, and
proteinuria <1 g/day. Treatment failure was deﬁned as requiring
supplemental immunosuppression, doubling of the serum creati-
nine, or death. The renal relapse was deﬁned as doubling of the
urine protein-to-creatinine ratio or by an increase in the serum
creatinine to 1 & 1/2 times above normal.
Results: Mean serum creatinine at the time of initiating treatment
was 1.8 mg/dL. and mean urine protein excretion of 3.5 g/day. 7 of
the 40 patients (17.5%) experienced treatment failure, while rest of
all patients achieved remission (partial or complete) during induc-
tion phase. All seven treatment failure patients progressed to CKD,
as they could not afford other therapies/modalities available for
further treatment. Maintenance therapy with azathioprine was well
tolerated. 7 of 33 patients in remission developed renal ﬂares which
were treated successfully with pulse steroids followed by tapering
of steroids over 6 months.
Conclusions: Cyclophosphamide as an induction regimen followed
by maintenance with AZA is a viable and efﬁcient agent for the
treatment of proliferative lupus nephritis in a developing world
with economic constraints.
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Introduction: Lupus nephritis (LN) is one of the most serious
complications of systemic lupus erythematosus (SLE). Local MHC II
upregulation and a T cell rich inﬁltration suggest an antigen-spe-
ciﬁc immune response against kidney structures. Nevertheless, no
renal autoantigen is known at present.
Methods: The TCRß repertoire of peripheral blood and urinary T
cells was analyzed by TCRß chain sequencing and subsequent
sequence analysis. T cells from SLE Patients were stimulated with
different kidney lysates. Reactivity of T cells upon antigen stimu-
lation was tested using 3H+ Thymidin uptake in T cell libraries and
by detection of the activation markers CD40L and CD69 by ﬂow-
cytometry. Further renal candidate autoantigens were identiﬁedS21
